Notice Regarding Share Offering

Overview of Share Offering and Share Buyback

At the board meeting on March 30, 2026, Mochida Pharmaceutical Co., Ltd. resolved to have the underwriting group, led by Mitsubishi UFJ Morgan Stanley Securities, purchase 1,153,600 ordinary shares through a share offering. The offering price will be determined based on the closing price on the Tokyo Stock Exchange during the period from April 6 to April 9, 2026. Additionally, there is a possibility of an additional share offering of up to 173,000 shares as an over-allotment, which will be priced in the same manner. Furthermore, it was also decided to implement a share buyback starting May 18, 2026, with upper limits of 2,000,000,000 yen and 530,000 shares.

Purpose of the Offering and Impact on Shareholders

This share offering aims to accelerate growth strategies and strengthen the stable profit base for the generic drug and biosimilar businesses according to the Mochida Pharmaceutical Group’s medium-term management plan. In addition, in line with the reduction of policy holdings, it seeks to promote stock ownership among individual investors to enhance stock liquidity and gain long-term strategic understanding. The sellers are Taisho Pharmaceutical Holdings and Sumitomo Pharma, with a lock-up period set at 180 days from the share offering price determination date. This is expected to lead to changes in shareholder composition and improvements in capital efficiency.